Erratum: Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase: Erratum.


Journal

Theranostics
ISSN: 1838-7640
Titre abrégé: Theranostics
Pays: Australia
ID NLM: 101552395

Informations de publication

Date de publication:
2021
Historique:
entrez: 5 3 2021
pubmed: 6 3 2021
medline: 6 3 2021
Statut: epublish

Résumé

[This corrects the article DOI: 10.7150/thno.23177.].

Identifiants

pubmed: 33664874
doi: 10.7150/thno.58558
pii: thnov11p3963
pmc: PMC7914359
doi:

Types de publication

Published Erratum

Langues

eng

Sous-ensembles de citation

IM

Pagination

3963

Commentaires et corrections

Type : ErratumFor

Informations de copyright

© The author(s).

Auteurs

Jiang-Kai Dong (JK)

Department of Pharmacology and Chemical Biology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Shanghai Universities Collaborative Innovation Center for Translational Medicine, Shanghai 200025, China.

Hui-Min Lei (HM)

Department of Pharmacology and Chemical Biology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Shanghai Universities Collaborative Innovation Center for Translational Medicine, Shanghai 200025, China.

Qian Liang (Q)

Department of Pharmacology and Chemical Biology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Shanghai Universities Collaborative Innovation Center for Translational Medicine, Shanghai 200025, China.

Ya-Bin Tang (YB)

Department of Pharmacology and Chemical Biology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Shanghai Universities Collaborative Innovation Center for Translational Medicine, Shanghai 200025, China.

Ye Zhou (Y)

Department of Pharmacology and Chemical Biology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Shanghai Universities Collaborative Innovation Center for Translational Medicine, Shanghai 200025, China.

Yang Wang (Y)

Department of Pharmacology and Chemical Biology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Shanghai Universities Collaborative Innovation Center for Translational Medicine, Shanghai 200025, China.

Shengzhe Zhang (S)

State Key Laboratory of Oncogenes and Related Genes, Renji-Med X Clinical Stem Cell Research Center, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China.

Wen-Bin Li (WB)

Department of Pharmacology and Chemical Biology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.

Yunguang Tong (Y)

Basic Medical College, Xinxiang Medical University, Xinxiang 453003, Henan, China.
Department of Medicine, Cedars-Sinai Medical Center, University of California Los Angeles School of Medicine, Los Angeles, CA 90048, United States.

Guanglei Zhuang (G)

State Key Laboratory of Oncogenes and Related Genes, Renji-Med X Clinical Stem Cell Research Center, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China.

Liang Zhang (L)

Department of Pharmacology and Chemical Biology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Shanghai Universities Collaborative Innovation Center for Translational Medicine, Shanghai 200025, China.

Hong-Zhuan Chen (HZ)

Department of Pharmacology and Chemical Biology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Shanghai Universities Collaborative Innovation Center for Translational Medicine, Shanghai 200025, China.

Liang Zhu (L)

Department of Pharmacology and Chemical Biology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Shanghai Universities Collaborative Innovation Center for Translational Medicine, Shanghai 200025, China.

Ying Shen (Y)

Department of Pharmacology and Chemical Biology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Shanghai Universities Collaborative Innovation Center for Translational Medicine, Shanghai 200025, China.

Classifications MeSH